IL23A and psoriasis: Monoclonal antibodies that specifically suppress IL-23 have been demonstrated to significantly reduce or even completely eradicate skin lesions in psoriasis patients, suggesting that IL-23 are fundamental to the development of psoriatic lesions (58).